Ionis Pharmaceuticals (IONS) Non-Current Assets (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Non-Current Assets of $503.2 million for Q2 2026, up 23.35% year-over-year from $408.0 million in Q2 2025, and down 1.91% quarter-over-quarter from $513.0 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Non-Current Assets (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $503.2 million for Q2 2026.
- In Q2 2026, Non-Current Assets rose 23.35% year-over-year to $503.2 million; the TTM figure through Jun 2026 stood at $2.1 billion (up 32.91% YoY), while the FY2025 annual figure was $533.2 million, up 39.08% from the prior year.
- Non-Current Assets for Q2 2026 stood at $503.2 million, down from $513.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $533.2 million in Q4 2025, with the low at $265.0 million in Q2 2022.
- The 5-year median for Non-Current Assets is $358.1 million (2023), against an average of $380.7 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets increased 1.65% in 2024, then surged 39.99% in 2025.
- Ionis Pharmaceuticals' Non-Current Assets stood at $331.2 million in 2022, then gained by 5.14% to $348.2 million in 2023, then grew by 10.1% to $383.4 million in 2024, then jumped by 39.08% to $533.2 million in 2025, then fell by 5.62% to $503.2 million in 2026.
- Business Quant data shows IONS's Non-Current Assets at $503.2 million in Q2 2026, $513.0 million in Q1 2026, and $533.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 503.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 503.23 Mn |
| Mar 31, 2026 | 513.02 Mn |
| Dec 31, 2025 | 533.20 Mn |
| Sep 30, 2025 | 514.10 Mn |
| Jun 30, 2025 | 407.98 Mn |
| Mar 31, 2025 | 394.02 Mn |
| Dec 31, 2024 | 383.39 Mn |
| Sep 30, 2024 | 367.25 Mn |
| Jun 30, 2024 | 361.75 Mn |
| Mar 31, 2024 | 348.25 Mn |
| Dec 31, 2023 | 348.22 Mn |
| Sep 30, 2023 | 349.32 Mn |
| Jun 30, 2023 | 354.38 Mn |
| Mar 31, 2023 | 342.60 Mn |
| Dec 31, 2022 | 331.18 Mn |
| Sep 30, 2022 | 269.85 Mn |
| Jun 30, 2022 | 264.99 Mn |
| Mar 31, 2022 | 265.97 Mn |
| Dec 31, 2021 | 266.64 Mn |
| Sep 30, 2021 | 259.15 Mn |